Umecrine Cognition announces publication in the Journal of Hepatology of the results of a pilot study of golexanolone in patients with hepatic encephalopathy
Umecrine Cognition to present clinical Phase 2a results at AASLD International Liver Meeting
Umecrine Cognition announces positive additional endpoint data from a phase 2a study with golexanolone in hepatic encephalopathy
Umecrine Cognition announces top-line results from its phase 2a study with golexanolone in hepatic encephalopathy
Umecrine Cognition announces a Notice of Allowance from USPTO for a patent protecting a pharmaceutical formulation of its proprietary lead compound golexanolone
Umecrine Cognition announces completion of enrollment in clinical Phase 2a study with golexanolone in patients with liver cirrhosis and hepatic encephalopathy
Umecrine Cognition announces first patient included in part D in clinical Phase 2a study with GR3027 in patients with liver cirrhosis and hepatic encephalopathy
Umecrine Cognition announces results from a Phase 2a study of GR3027 in patients with idiopathic hypersomnia
Umecrine Cognition granted a European patent protecting its lead candidate drug GR3027
Umecrine Cognition appoints Dr. Eva Arlander as Chief Development Officer
Umecrine Cognition announces on-line publication of Clinical trial results perteining to GR3027 safety, pharmacokinetics and CNS target engagement
Umecrine Cognition announces first patient included in clinical Phase 2a study in patients with sleep disorder
Umecrine Cognition raises SEK 20 million to treat unmet needs in sleep disorder
Umecrine Cognition announces positive data from its Phase 1b study of GR3027 - a potential new treatment of hepatic encephalopathy
Umecrine Cognition appoints Dr. Thomas P. Blackburn to its board of directors
Umecrine Cognition to present at the EASL International Liver Congress 2017
Umecrine Cognition announces first patient included in Clinical Phase 1b/2a study with GR3027, a novel drug candidate for Hepatic Encephalopathy
Umecrine Cognition raises SEK 45 million to advance GR3027, a novel drug candidate for hepatic encephalopathy
Positive Phase 1 top line data with GR3027 demonstrate safety, tolerability, and CNS target engagement
Umecrine Cognition appoints Dr. Bruce Scharschmidt to its board of directors.
Umecrine Cognition raises new funds to support clinical development of novel drug candidate GR3027 for Hepatic Encephalopathy - Phase I clinical trial initiated.
Umecrine Cognition announces grant of a US patent protecting its lead candidate drug GR3027.
GR3027 normalizes the neurolological symptoms in two preclinical models of Hepatic Encephalopathy.
Umecrine Cognition signs partnering agreement with CleveXel Pharma.
Magnus Doverskog appointed as new CEO for Umecrine Cognition.
Images and Logos
JPEG, RGB 165 K
Logo - High Quality
JPEG, 300 PPI, CMYK 503 K
Logo - Low Quality
JPEG, 72 PPI, RGB 71 K